On-Demand CME Videos

Therapeutic Hotline: Expert Perspectives on IL17 Inhibitors in Targeted Management of Inflammatory Skin Disorders


This activity is supported by an educational grant from UCB.


In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:

Release Date:

August 15, 2023

Expiration Date:

August 15, 2024

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Explain the role of the IL-17 pathway in the pathophysiology of chronic inflammatory dermatologic disorders

  • Review data for IL-17 inhibitors for the management of inflammatory dermatologic disorders

  • Discuss strategies to educate patients about IL-17 inhibitors and incorporate these agents into clinical care

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Mark Lebwohl, MD

Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Ronald Vender, MD, FRCPC

Dermatrials Research Inc & Venderm Consulting
Associate Clinical Professor of Medicine
McMaster University
Hamilton, Canada

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers


In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

Mark Lebwohl, MD

Grant/Research Support: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Novartis, Ortho Dermatologics, Regeneron, and UCB, Inc.

Consultant: AnaptysBio, Arcutis, Inc., Arena Pharmaceuticals, Aristea Therapeutics, Avotres Therapeutics, BioMX, Boehringer-Ingelheim, Brickell Biotech, Cara Therapeutics, Castle Biosciences, Corevitas, Dermavant Sciences, Evommune, Inc., Facilitation of International Dermatology Education, Hexima Ltd., Meiji Seika Pharma, Mindera, National Society of Cutaneous Medicine, New York College of Podiatric Medicine, Pfizer, Seanergy, SUN Pharma, Verrica, and Vial.

Ronald B. Vender, MD, FRCPC

Advisory Board/Consultant: Abbvie, Actelion, Amgen, Aralez, Arcutis, Bausch-Health, Boehringer Ingelheim, BMS, Celgene, Cipher, Janssen, Galderma, GSK, Kabi-Care, Leo, Lilly, Merck,
Novartis, Palladin, Pfizer, Sandoz, SUN, UCB, Viatris-Mylan

Grant/Research Support: Abbvie, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, BMS, Celgene,
Centocor, Dermira, Dermavant, Galderma, GSK, Innovaderm, Janssen, Leo, Lilly, Meiji, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, Takeda, UCB

Speaker's Bureau: Abbvie, Actelion, Amgen, Arcutis, Bausch-Health, BMS, Celgene, Cipher, Janssen, Galderma, GSK, Leo, Lilly, Merck, Novartis, Pfizer, Sun, UCB

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The Institute discloses that all relevant conflicts have been satisfactorily mitigated.